Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Quest Diagnostics (NY: DGX )

162.44 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
ConferMED Awarded Grant From the Quest Diagnostics Foundation To Provide Specialty eConsults to Front Line Providers at Federally Qualified Health Centers in Key Regions
SOURCE: Quest Diagnostics 
Via 3BL Media
Quest for Health Equity Offers No Cost Wellness Screenings at Baltimore Community Event
SOURCE: Quest Diagnostics 
Via 3BL Media
Quest Diagnostics Incorporated (NYSE:DGX) Shareholder Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/12/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Quest Diagnostics Incorporated. 
Via SBWire
7 Defensive Dividend Healthcare Stocks to Buy Now
As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. 
Via InvestorPlace
7 Oversold Stocks That Shouldn’t Be. Buy Them Now.
Consider these seven oversold stocks, as fear, uncertainty and doubt have knocked them down to too low a price. 
Via InvestorPlace
Analyst Ratings for Quest Diagnostics
Quest Diagnostics (NYSE:DGX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Analyst Ratings For Quest Diagnostics
Quest Diagnostics (NYSE:DGX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E... 
Via Benzinga
Quest Diagnostics' COVID-19 Testing Sales Decline 28% In Q1; Lifts FY22 EPS Guidance
Via Benzinga
Quest Diagnostics: Q1 Earnings Insights
Quest Diagnostics (NYSE:DGX) reported its Q1 earnings results on Thursday, April 21, 2022 at 06:45 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Quest Diagnostics Announces Organizational Changes to Accelerate Growth and Drive Operational Excellence
SOURCE: Quest Diagnostics 
Via 3BL Media
Quest Diagnostics's Earnings: A Preview
Quest Diagnostics (NYSE:DGX) is set to give its latest quarterly earnings report on Thursday, 2022-04-21. Here's what investors need to know before the announcement. Analysts estimate that Quest... 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Quest Diagnostics Secures CDC Contract To Support COVID-19 Research
Via Benzinga
Earnings Scheduled For February 3, 2022
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter. 
Via Benzinga
Earnings Scheduled For April 21, 2022
Companies Reporting Before The Bell • Heritage Financial (NASDAQ:HFWA) is likely to report quarterly earnings at $0.37 per share on revenue of $53.22 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022
Upgrades 
Via Benzinga
Positive Drug Tests Among US Workers Higher Than In Last 20 Years; Does That Include Cannabis?
Which of these is correct? The number of cannabis consumers has increased or more people have stopped concealing their consumption as marijuana legalization spreads across the United States?  
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Quest Diagnostics Incorporated (NYSE:DGX) Investor Notice: Investigation over Possible Securities Laws Violations
San Diego, CA -- (SBWIRE) -- 03/23/2022 -- Quest Diagnostics Incorporated was under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
7 Healthcare Stocks to Buy for the Long Term
When the markets go through the massive transitions they're seeing right now, it's a great time to add quality healthcare stocks. 
Via InvestorPlace
This Foreboding Sign Looms Over Quest Diagnostics's Chart
If history is any guide, there may be trouble ahead for shares of Quest Diagnostics (NYSE:DGX). A so-called "death cross" has formed on its chart and, not surprisingly, this... 
Via Benzinga
A Look Into Healthcare Sector Value Stocks
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples... 
Via Benzinga
What 8 Analyst Ratings Have To Say About Quest Diagnostics
Analysts have provided the following ratings for Quest Diagnostics (NYSE:DGX) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years.... 
Via FinancialNewsMedia
Exposures COVID-19
Quest Diagnostics Q4 Earnings, FY22 Reflects Lower Demand For COVID-19 Testing Services
Quest Diagnostics Incorporated (NYSE: DGX) posted a better-than-expected  
Via Benzinga
FORTUNE Magazine Names Quest Diagnostics One of 2022 "World's Most Admired Companies" For Eighth Consecutive Year
SOURCE: Quest Diagnostics 
Via 3BL Media
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Quest Diagnostics Q4 Earnings
  Quest Diagnostics (NYSE:DGX) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:45 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.